HOME >> BIOLOGY >> NEWS
3-D Structure of Human Tumor-Suppressor Protein Produced

COLUMBUS, Ohio -- Researchers here have determined the three-dimensional structure of the protein produced by one of the most important human tumor-suppressor genes.

The gene is the p16 tumor-suppressor gene. The protein produced by this gene, the p16 protein, normally prevents cells from dividing when they shouldn’t.

When this protein is missing or inactivated due to mutations in the p16 tumor-suppressor gene, cancer can occur. In fact, damage to the p16 protein is a factor in more than 70 different types of cancer.

The researchers have also produced computer-generated pictures of the protein.

“This was a major achievement because of the importance of this protein in cancer and because of the difficulty of the project,” said Ming-Daw Tsai, the researcher at Ohio State University’s Comprehensive Cancer Center who led the study.

“If we can develop a drug that mimics p16, that would be a potentially good approach for the treatment of cancer, which is the ultimate goal of work like this.

“Determining the structure of the protein is the first major step in developing such a drug,” said Tsai, a professor of chemistry and of biochemistry.

The study, conducted by Tsai and a team of Ohio State researchers, was published in a February issue of the journal Molecular Cell. They used nuclear magnetic resonance (NMR) spectroscopy to measure the location of the atoms within the protein and their distances from one another. This information was then fed into a computer to determine the molecule’s structure.

NMR spectroscopy uses a powerful magnetic field to make molecular measurements. The method enables the researchers to study the structure of the p16 protein in a water solution, which more closely represents the molecule’s structure as it would exist inside the cell.

This, in turn, will make it easier through further research to determine the protein’
'"/>

Contact: Ming-Daw Tsai
Tsai.7@osu.edu
(614) 292-3080
Ohio State University
2-Mar-1998


Page: 1 2

Related biology news :

1. Structure solved at Scripps shows how one human protein reduces potency of chemotherapy
2. Structure solved by Scripps scientists shows one way that body controls gene expression
3. Structure of a Nobel-prize winning molecule: Aquaporin
4. Structure of HIV-neutralizing antibody solved
5. Structure of key breast cancer receptor determined
6. Structure of cog at the hub of metabolism reveals anti-ageing function
7. Structure of pain-modulating enzyme described by scientists at the Scripps Research Institute
8. Structure reveals details of cells cargo-carriers
9. Structure of key receptor unlocked; Related proteins will fall like dominoes
10. New Science Press launches Proteins: From Sequence to Structure
11. Third piece completes deadly puzzle: Structure of anthrax toxin offers clues to treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Structure Human Tumor Suppressor Protein Produced

(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... 2014   EyeLock Inc. , a market ... MorphoTrust USA (Safran), a leading U.S. provider ... strategic partnership to offer comprehensive biometric identity solutions ... airport screening and financial services markets. ... consumers through a nationwide network of 1,100 IdentoGO® ...
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:11/21/2014)... The report, "Synthetic Biology ... Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene Synthesis, ... Bioremediation) - Global Forecast to 2018", analyses ... opportunities, and challenges. , Browse 99 market ... 185 pages and in-depth TOC of the ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... DIEGO , Nov. 20, 2014 ... has been dosed in its Phase 1 trial ... cisplatin for the treatment of malignant pleural mesothelioma ... Group is conducting clinical trials on ADI-PEG 20, ... agents, for the treatment of several other indications, ...
Breaking Biology Technology:Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
Cached News: